AbbVie Inc. (ABBV)

業務介紹

艾伯維公司在全球範圍內發現、開發、製造和銷售藥品。該公司提供以下產品:

HUMIRA,一種用於治療自身免疫性疾病和腸道貝赫切特病的注射療法;
SKYRIZI,用於治療成人中度到重度斑塊性牛皮癬;
RINVOQ,一種JAK抑制劑,用於治療成人中度到重度活動性類風濕性關節炎;
IMBRUVICA,用於治療成人慢性淋巴細胞白血病(CLL)、小淋巴細胞淋巴瘤(SLL)的成人患者;
VENCLEXTA,一種BCL-2抑制劑,用於治療CLL或SLL的成人患者;
MAVYRET,用於治療1-6型慢性丙型肝炎感染的患者。

該公司還提供CREON胰酶療法、Synthroid治療甲狀腺功能減退、Linzess/Constella治療便秘性腸易激綜合症和慢性特發性便秘、Lupron治療晚期前列腺癌、子宮內膜異位症和中樞性早熟性青春期以及因子宮肌瘤引起的貧血,以及Botox治療用藥。

此外,該公司還提供ORILISSA,一種非肽性小分子促性腺激素釋放激素拮抗劑,用於治療中度到重度子宮內膜異位症疼痛的女性;Duopa和Duodopa,一種治療帕金森病的左旋多巴-卡比多巴腸溶膠;Lumigan/Ganfort,一種用於降低開角型青光眼或眼高壓患者眼內壓的生物美托洛爾溶液;Ubrelvy,用於治療成人偏頭痛;Alphagan/Combigan,一種用於降低開角型青光眼患者眼內壓的α-腎上腺素受體激動劑;以及Restasis,一種用於增加淚液分泌的環孢素A眼藥水,以及其他眼科產品。



AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

公司網址

https://www.abbvie.com